StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
INNO.CN$3.61+0.00%
Fair $3.61+0.0%

INNO.CN

InnoCan Pharma Corporation

Consumer Defensive / Household & Personal ProductsCanadian Sec

$3.61

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $3.61Fund rank 29/100 · Data gapFallback financials|
SA 26/D
F-Score: 5/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-1.6M · quality 52.3/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 18/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

26/100

D

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -20.1%, below the 5% threshold
Thesis & Journal · INNO.CNLocal privado en este navegador · InnoCan Pharma Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$16M

P/E

N/A

•

EV/EBITDA

80.0x

↑

ROE

-20.1%

↓

Gross Margin

89.9%

↑

Debt/Equity

0.17

↓
52-Week Range$4
$3$21

TradingView lightweight chart

INNO.CN price, volumen y niveles de valoración

Último $3.610Periodo -77.8%
Fair value: $3.610

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+118.3%

FCF CAGR

—

FCF margin

1.8%

FCF / Net income

-0.43x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $26.6M · net income $-1.1M · FCF $479000.0

2022-FY → 2025-FY

Gross margin

89.9%+7.6% pts

Operating margin

-4.7%+240.1% pts

Net margin

-4.2%+142.9% pts

FCF margin

1.8%+239.9% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$26.6M$26.6M$29.4M$13.7M$2.6M
Net Income$-1.1M$-1.1M$-1.8M$-4.7M$-3.8M
EBITDA$130000.00$130000.00$961000.00$-4.0M$-3.9M
EPS-0.25-0.25-0.65-1.30-1.04
Gross Margin89.9%89.9%89.0%87.7%82.3%
Operating Margin-4.7%-4.7%-4.2%-27.8%-244.9%
Net Margin-4.2%-4.2%-6.2%-34.4%-147.1%
Balance Sheet
Debt/Equity0.170.170.000.010.01
Current Ratio7.707.70———
Cash Flow
Free Cash Flow$479000.00$479000.00$-1.6M$-4.0M$-6.1M
Returns
ROE-20.1%-20.1%-35.5%-114.6%-58.9%
Valuation
EV/EBITDA80.0480.0453.08——
P/B2.892.8910.8420.989.54
Growth & Yield
Revenue Growth-9.6%-9.6%115.5%433.7%—
EPS Growth61.5%61.5%50.0%-25.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -67.3%

Total return

-67.3%

Start / end P/E

n/dx → n/dx

EPS bridge

-0.65 → -0.25

Residual

-67.3%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-67.3%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.